IJMDC. 2020; 4(11): 1993-1995

Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes: a short review

Authors: Ibrahim Mahmoud H Ajwah, Waleed Jamal Aloqbi, Ahmed Ebrahim Al Ansari, Nawaf Saeed Almalki, Abdulelah Hamdan Alonizei, Razan Faisal Aljohani, Omniyyah Ahmed Alnahyah, Razan Kamel Albalawi, Sultan Makki Alsharef, Abdulrahman Abdulhadi Alatawi, Afnan Mohammed Almutairi, Wedad Eid Aljthli, Amirah Naif Albalawi, Mohammed A. Alotaibi, Mohammed Abdullah Alasmari, Atheer Hammad Alatawi.

ABSTRACT

Type 2 diabetes is a chronic and progressive disease associated with a series of complications, including major adverse cardiovascular events. As adequate glycemic control has been proven to reduce this risk, sodium-glucose cotransporter 2 (SGLT2) inhibitors are among the promising medications in managing patients with type 2 diabetes. The current systematic review aimed to explore the SGLT2 inhibitor effects on cardiovascular outcomes. A filtration procedure was used to remove duplicates and irrelevant publications. The online databases such as PubMed, Google Scholar, and EBSCO were used to perform a literature search, without any date or language restrictions. We used a combination of relevant search terms “diabetes, sodium-glucose cotransporter 2 inhibitors, and cardiovascular." We independently identified publications and systematically screened titles, abstracts, and full texts of the collected publications. Among 200 articles initially selected based on the title and abstract, 197 articles were excluded. Finally, three articles were selected and included in the review. All three studies concerned about the cardiovascular safety of SGLT2 inhibitors and showed that, compared with placebo, empagliflozin, canagliflozin, and dapagliflozin safely lower blood glucose with a reduction in the major adverse cardiovascular events. Across the three trials, empagliflozin, canagliflozin, and dapagliflozin resulted in a consistent class effect on cardiovascular outcomes.

Keywords:
Cardiovascular events, SGLT2 inhibitor, diabetes.‎


View PDF
Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes: a short review


Authors
Ibrahim Mahmoud H Ajwah
Internal Medicine Department, King Salman Armed Formed Hospital, Tabuk, Saudi Arabia
PubMed articlesGoogle scholar articles

Waleed Jamal Aloqbi
Pediatric Department, Ministry of Health, Riyadh, Saudi Arabia
PubMed articlesGoogle scholar articles

Ahmed Ebrahim Al Ansari
Internal Medicine Department, Security Forces Hospital, Riyadh, Saudi Arabia
PubMed articlesGoogle scholar articles

Nawaf Saeed Almalki
Collage of Medicine, University of Tabuk, Tabuk, Saudi Arabia
PubMed articlesGoogle scholar articles

Abdulelah Hamdan Alonizei
Collage of Medicine, University of Tabuk, Tabuk, Saudi Arabia
PubMed articlesGoogle scholar articles

Razan Faisal Aljohani
Collage of Medicine, University of Tabuk, Tabuk, Saudi Arabia
PubMed articlesGoogle scholar articles

Omniyyah Ahmed Alnahyah
Collage of Medicine, University of Tabuk, Tabuk, Saudi Arabia
PubMed articlesGoogle scholar articles

Razan Kamel Albalawi
Internal Medicine Department, Security Forces Hospital, Riyadh, Saudi Arabia
PubMed articlesGoogle scholar articles

Sultan Makki Alsharef
Collage of Medicine, University of Tabuk, Tabuk, Saudi Arabia
PubMed articlesGoogle scholar articles

Abdulrahman Abdulhadi Alatawi
Collage of Medicine, University of Tabuk, Tabuk, Saudi Arabia
PubMed articlesGoogle scholar articles

Afnan Mohammed Almutairi
Collage of Medicine, University of Tabuk, Tabuk, Saudi Arabia
PubMed articlesGoogle scholar articles

Wedad Eid Aljthli
Collage of Medicine, University of Tabuk, Tabuk, Saudi Arabia
PubMed articlesGoogle scholar articles

Amirah Naif Albalawi
Collage of Medicine, University of Tabuk, Tabuk, Saudi Arabia
PubMed articlesGoogle scholar articles

Mohammed A Alotaibi
Collage of Medicine, University of Tabuk, Tabuk, Saudi Arabia
PubMed articlesGoogle scholar articles

Mohammed Abdullah Alasmari
Collage of Medicine, University of Tabuk, Tabuk, Saudi Arabia
PubMed articlesGoogle scholar articles

Atheer Hammad Alatawi
Collage of Medicine, University of Tabuk, Tabuk, Saudi Arabia.
PubMed articlesGoogle scholar articles


Correspondence to:
. Internal Medicine Department, King Salman Armed Formed Hospital, Tabuk, Saudi Arabia.; aj.wa@hotmail.com

Publication history
Received 12 Sep 2020
Accepted 30 Sep 2020
Published online 07 Oct 2020
Published in print 05 Nov 2020

How to cite this article?

Export to EndNote Export to refMan

Pubmed Style

Ajwah IMH, Aloqbi WJ, Ansari AEA, Almalki NS, Alonizei AH, Aljohani RF, Alnahyah OA, Albalawi RK, Alsharef SM, Alatawi AA, Almutairi AM, Aljthli WE, Albalawi AN, Alotaibi MA, Alasmari MA, Alatawi AH. Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes: a short review. IJMDC. 2020; 4(11): 1993-1995. doi:10.24911/IJMDC.51-1599914173


Web Style

Ajwah IMH, Aloqbi WJ, Ansari AEA, Almalki NS, Alonizei AH, Aljohani RF, Alnahyah OA, Albalawi RK, Alsharef SM, Alatawi AA, Almutairi AM, Aljthli WE, Albalawi AN, Alotaibi MA, Alasmari MA, Alatawi AH. Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes: a short review. http://www.ijmdc.com/?mno=134451 [Access: January 27, 2021]. doi:10.24911/IJMDC.51-1599914173


AMA (American Medical Association) Style

Ajwah IMH, Aloqbi WJ, Ansari AEA, Almalki NS, Alonizei AH, Aljohani RF, Alnahyah OA, Albalawi RK, Alsharef SM, Alatawi AA, Almutairi AM, Aljthli WE, Albalawi AN, Alotaibi MA, Alasmari MA, Alatawi AH. Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes: a short review. IJMDC. 2020; 4(11): 1993-1995. doi:10.24911/IJMDC.51-1599914173


Vancouver/ICMJE Style

Ajwah IMH, Aloqbi WJ, Ansari AEA, Almalki NS, Alonizei AH, Aljohani RF, Alnahyah OA, Albalawi RK, Alsharef SM, Alatawi AA, Almutairi AM, Aljthli WE, Albalawi AN, Alotaibi MA, Alasmari MA, Alatawi AH. Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes: a short review. IJMDC. (2020), [cited January 27, 2021]; 4(11): 1993-1995. doi:10.24911/IJMDC.51-1599914173


Harvard Style

Ajwah, I. M. H., Aloqbi, . W. J., Ansari, . A. E. A., Almalki, . N. S., Alonizei, . A. H., Aljohani, . R. F., Alnahyah, . O. A., Albalawi, . R. K., Alsharef, . S. M., Alatawi, . A. A., Almutairi, . A. M., Aljthli, . W. E., Albalawi, . A. N., Alotaibi, . M. A., Alasmari, . M. A. & Alatawi, . A. H. (2020) Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes: a short review. IJMDC, 4 (11), 1993-1995. doi:10.24911/IJMDC.51-1599914173


Turabian Style

Ajwah, Ibrahim Mahmoud H, Waleed Jamal Aloqbi, Ahmed Ebrahim Al Ansari, Nawaf Saeed Almalki, Abdulelah Hamdan Alonizei, Razan Faisal Aljohani, Omniyyah Ahmed Alnahyah, Razan Kamel Albalawi, Sultan Makki Alsharef, Abdulrahman Abdulhadi Alatawi, Afnan Mohammed Almutairi, Wedad Eid Aljthli, Amirah Naif Albalawi, Mohammed A. Alotaibi, Mohammed Abdullah Alasmari, and Atheer Hammad Alatawi. 2020. Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes: a short review. International Journal of Medicine in Developing Countries, 4 (11), 1993-1995. doi:10.24911/IJMDC.51-1599914173


Chicago Style

Ajwah, Ibrahim Mahmoud H, Waleed Jamal Aloqbi, Ahmed Ebrahim Al Ansari, Nawaf Saeed Almalki, Abdulelah Hamdan Alonizei, Razan Faisal Aljohani, Omniyyah Ahmed Alnahyah, Razan Kamel Albalawi, Sultan Makki Alsharef, Abdulrahman Abdulhadi Alatawi, Afnan Mohammed Almutairi, Wedad Eid Aljthli, Amirah Naif Albalawi, Mohammed A. Alotaibi, Mohammed Abdullah Alasmari, and Atheer Hammad Alatawi. "Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes: a short review." International Journal of Medicine in Developing Countries 4 (2020), 1993-1995. doi:10.24911/IJMDC.51-1599914173


MLA (The Modern Language Association) Style

Ajwah, Ibrahim Mahmoud H, Waleed Jamal Aloqbi, Ahmed Ebrahim Al Ansari, Nawaf Saeed Almalki, Abdulelah Hamdan Alonizei, Razan Faisal Aljohani, Omniyyah Ahmed Alnahyah, Razan Kamel Albalawi, Sultan Makki Alsharef, Abdulrahman Abdulhadi Alatawi, Afnan Mohammed Almutairi, Wedad Eid Aljthli, Amirah Naif Albalawi, Mohammed A. Alotaibi, Mohammed Abdullah Alasmari, and Atheer Hammad Alatawi. "Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes: a short review." International Journal of Medicine in Developing Countries 4.11 (2020), 1993-1995. Print. doi:10.24911/IJMDC.51-1599914173


APA (American Psychological Association) Style

Ajwah, I. M. H., Aloqbi, . W. J., Ansari, . A. E. A., Almalki, . N. S., Alonizei, . A. H., Aljohani, . R. F., Alnahyah, . O. A., Albalawi, . R. K., Alsharef, . S. M., Alatawi, . A. A., Almutairi, . A. M., Aljthli, . W. E., Albalawi, . A. N., Alotaibi, . M. A., Alasmari, . M. A. & Alatawi, . A. H. (2020) Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes: a short review. International Journal of Medicine in Developing Countries, 4 (11), 1993-1995. doi:10.24911/IJMDC.51-1599914173


Share this article

Click the icon of the social media platform on which you would like to share this article.

Article Statistics

Request permissions

If you wish to reuse any part or all of this article please contact the copyright holder, contact@ijmdc.com.

Copyright ©2021 Discover STM Publishing. All Rights Reserved.